Crown LiquidationCo NV in liquidatie 最近的每股收益为 $, $-0.27 的预期。
Crown LiquidationCo NV in liquidatie CNTGF 上一季度的收入表现如何?
Crown LiquidationCo NV in liquidatie 上一季度的收入为 $
Crown LiquidationCo NV in liquidatie 的收入预期是多少?
根据 位华尔街分析师的预测,Crown LiquidationCo NV in liquidatie 的收入预期范围从 $ 到 $
Crown LiquidationCo NV in liquidatie 的盈利质量评分是多少?
Crown LiquidationCo NV in liquidatie 的盈利质量评分为 B+/56.12154。该评分基于盈利能力、增长、现金生成与资本分配以及杠杆四个维度。
Crown LiquidationCo NV in liquidatie 何时发布财报?
Crown LiquidationCo NV in liquidatie 的下一份财报预计在 2024-12-03 发布
Crown LiquidationCo NV in liquidatie 的预期收益是多少?
根据华尔街分析师的预测,Crown LiquidationCo NV in liquidatie 的预期收益为 $14.93M
Crown LiquidationCo NV in liquidatie 是否超出收益预期?
Crown LiquidationCo NV in liquidatie 最近的收益为 $, 预期。
关键数据
前收盘价
$0.12
开盘价
$0.1017
当日区间
$0.1017 - $0.12
52周范围
$0.0003 - $0.705
交易量
3.9K
平均成交量
5.8K
股息收益率
--
每股收益(TTM)
-2.14
市值
$3.3M
什么是 CNTGF?
Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company is headquartered in Rostock, Mecklenburg-Vorpommern and currently employs 493 full-time employees. The company went IPO on 2019-11-07. The firm focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The firm's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The firm's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The firm's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.